个人简介：

陈敏锋，男，研究员，硕士生导师。2010年毕业于广州中医药大学中药学院，获学士学位。2015年毕业于暨南大学中药学专业，获博士学位。2015年进入暨南大学中西医结合博士后流动站进行博士后研究。2018年12月进入暨南大学药学院工作。主持国家自然科学基金2项、广东省自然科学基金3项、其他省市级科研项目3项。以第一作者/通讯作者（含共同）在Gut、Nat Meta、J Clin Invest（2篇）、Drug Resist Updates、Adv Sci（2篇）等本领域权威杂志发表SCI收录论文22篇。申请PCT国际发明专利2项，获得授权国际发明专利8项（包括美国专利、日本专利、澳大利亚专利、印度专利、欧洲专利、英国专利、德国专利和法国专利各1项）、授权中国发明专利6项。入选2022年广东省科协青年科技人才培育计划，广东省自然科学基金-杰出青年基金项目获得者（2024年）。

研究方向

1.周细胞介导肿瘤转移和血管靶向药物的调控机制

2.周细胞靶向抗肿瘤候选新药研究

代表性论文

1. Li XB#, Pan JH#, Liu TZ#, Yin WQ, Miao Q, Zhao Z, Gao YF, Zheng W, Li H, Deng R, Huang DD, Qiu SH, Zhang YR, Qi Q, Deng LJ, Huang MH, Tang Ming-Kuen Patrick, Cao YH*, Chen MF*, Ye WC*, Zhang DM*. Novel TCF21high pericyte subpopulation promotes colorectal cancer metastasis by remodeling perivascular matrix. Gut, 2023;72(4):710-721.

2. Wang CR#, Huang MH#, Lin YN#, Zhang YM, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 to confer resistance to antiangiogenic therapy. Nat Metab, 2023; 5(10):1765-1786.

3. Wen Q#, Huang MH#, Xie JW#, Liu RY#, Miao Q, Huang JJ, Zhang JQ, Lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen ZS*, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resist Updat. 2023;69:100975.

4. Qi M#, Fan SR#, Huang MH#, Pan JH, Li Y, Miao Q, Lyu WY, Li XB, Deng LJ, Qiu SH, Liu TZ, Deng WQ, Chu XD, Jiang C, He WZ, Xia LP, Yang YL, Hong J, Qi Q, Yin WQ, Liu XN, Shi CZ, Chen MF*, Ye WC*, Zhang DM*. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to anti-angiogenics in colorectal cancer liver metastasis models. J Clin Invest, 2022;132(19): e157399.

5. Chen MF#, Lei XP#, Shi CZ, Huang MH, Li XB, Wu BJ, Li ZQ, Han WL, Du B, Hu JY, Nie QL, Mai WQ, Ma N, Xu NH, Zhang XY, Fan CL, Hong AH, Xia MH, Luo LP, Ma AD, Li HS, Yu Q, Chen HR*, Zhang DM*, Ye WC*. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest, 2017;127(10): 3689-3701.

6. Li XB#, Qi Q#, Li Y, Miao Q, Yin WQ, Pan JH, Zhao Z, Chen XY, Yang F, Zhou XF, Huang MH, Wang CR, Deng LJ, Huang DD, Qi M, Fan SR, Zhang YR, Qiu SH, Deng WQ, Liu TZ, Chen MF*, Ye WC*, Zhang DM*. TCAF2 in pericytes promotes colorectal cancer liver metastasis via inhibiting cold-sensing TRPM8 channel. Adv Sci, 2023; 10(30):e2302717. 

7. Fan SR#, Qi M#, Qi Q#, Miao Q, Deng LJ, Pan JH, Qiu SH, He JS, Huang MH, Li XB, Lin JP, Huang J, Lyu WY, Deng WQ, He YY, Liu XS, Gao LF*, Zhang DM*, Ye WC*, Chen MF*. Targeting FAPα-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis. Acta Pharm Sin B, 2024;14(2):682-697.

8. Ran Y #, Xu ZY#, Chen MF#, Wang W#, Wu Y, Cai JX, Long JQ, Chen ZS, Zhang DM*, Guan BO*. Fiber-optic theranostics (FOT): Interstitial fiber-optic needles for cancer sensing and therapy. Adv Sci, 2022; 9: e2200456.

9. Huang MH#, Chen MF#, Qi M, Ye GN, Pan JH, Shi CZ, Yang YL, Zhao LY, Mo XK, Zhang YR, Li Y, Zhong JC, Lu WJ, Li XB, Zhang JY, Lin JR, Luo LP, Liu TZ, Patrick MK Tang, Hong A, Cao YH*, Ye WC*, Zhang DM*. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J Extracell Vesicles. 2021;10:e12096. 

10. Ye GN#, Jiao YB#, Deng LJ#, Cheng MJ, Wang S, Zhang JQ, Jie Ouyang J, Li Y, He YX, Tu ZC, Wang Z, Song XJ, Wang CR, Qi Q, Zhang DM, Wang L*, Huang MH*, Ye WC*, Chen MF*. Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway. Int J Biol Sci, 2023; 19(14):4376-4392.